Gongjin-Dan Enhances Hippocampal Memory in a Mouse Model of Scopolamine-Induced Amnesia
Jin-Seok Lee, Sung-Shin Hong, Hyeong-Geug Kim, Hye-Won Lee, Won-Yong Kim, Sam-Keun Lee, Chang-Gue Son, Jin-Seok Lee, Sung-Shin Hong, Hyeong-Geug Kim, Hye-Won Lee, Won-Yong Kim, Sam-Keun Lee, Chang-Gue Son
Abstract
We evaluated the neuropharmacological effects of Gongjin-Dan (GJD) on the memory impairment caused by scopolamine injection. BALB/c mice were orally treated with GJD (100, 200, or 400 mg/kg, daily) or tacrine (THA, 10 mg/kg) for 10 days, and scopolamine (2 mg/kg) was injected intraperitoneally. The radial arm maze and passive avoidance tests were performed to evaluate the animal's learning and memory. Scopolamine increased the task completing time, the number of total errors (reference and working memory error) in the radial arm maze task, and the latency time in the passive avoidance test, which were significantly ameliorated by treatment with GJD. The GJD treatment also attenuated the scopolamine-induced hyperactivation of acetylcholinesterase activity, and suppression of the expression of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and their receptors in the hippocampus. These effects of GJD were supported by both the doublecortin (DCX)-positive staining and Nissl staining, which were used to measure hippocampal neurogenesis and atrophy, respectively. These findings strongly suggest that GJD exerts a potent anti-amnesic effect, and its underlying mechanism might involve the modulation of cholinergic activity.
Conflict of interest statement
Competing Interests: The authors declare that no conflicts of interest exist. All the authors have approved the final article.
Figures
References
- Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends Alzheimer's Disease International; 2015.
- Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2006;27(10):1372–84. doi: S0197-4580(05)00283-6 .
- Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet. 2011;377(9770):1019–31. 10.1016/S0140-6736(10)61349-9 .
- Blake MG, Krawczyk MC, Baratti CM, Boccia MM. Neuropharmacology of memory consolidation and reconsolidation: Insights on central cholinergic mechanisms. J Physiol Paris. 2014;108(4–6):286–91. 10.1016/j.jphysparis.2014.04.005 .
- Kenney JW, Gould TJ. Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine. Mol Neurobiol. 2008;38(1):101–21. 10.1007/s12035-008-8037-9 ; PMCID: PMC2683366.
- Tyler WJ, Perrett SP, Pozzo-Miller LD. The role of neurotrophins in neurotransmitter release. Neuroscientist. 2002;8(6):524–31. ; PMCID: PMC2810653.
- Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379–97. 148/5/379 .
- Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 2013;11(3):315–35. Epub 2013/11/02. 10.2174/1570159X11311030006 ; PMCID: PMC3648782.
- Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211–25. ; PMCID: PMC2546466.
- Mimica N, Presecki P. Side effects of approved antidementives. Psychiatr Danub. 2009;21(1):108–13. PubMed .
- Amieva H, Meillon C, Helmer C, Barberger-Gateau P, Dartigues JF. Ginkgo biloba extract and long-term cognitive decline: a 20-year follow-up population-based study. PLoS One. 2013;8(1):e52755 10.1371/journal.pone.0052755 ; PMCID: PMC3543404.
- Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011;76(16):1389–94. 10.1212/WNL.0b013e318216eb7b ; PMCID: PMC3269774.
- UNESCO. Memory of the World. Available: . 2009.
- Moon E, Her Y, Lee JB, Park JH, Lee EH, Kim SH, et al. The multi-herbal medicine Gongjin-dan enhances memory and learning tasks via NGF regulation. Neurosci Lett. 2009;466(3):114–9. 10.1016/j.neulet.2009.09.033 .
- Sunwoo YY, Park SI, Chung YA, Lee J, Park MS, Jang KS, et al. A Pilot Study for the Neuroprotective Effect of Gongjin-dan on Transient Middle Cerebral Artery Occlusion-Induced Ischemic Rat Brain. Evid Based Complement Alternat Med. 2012;2012:682720 10.1155/2012/682720 ; PMCID: PMC3375177.
- Hong SS, Lee JY, Lee JS, Lee HW, Kim HG, Lee SK, et al. The traditional drug Gongjin-Dan ameliorates chronic fatigue in a forced-stress mouse exercise model. J Ethnopharmacol. 2015;168:268–78. Epub 2015/04/14. 10.1016/j.jep.2015.04.001 .
- Falsafi SK, Deli A, Hoger H, Pollak A, Lubec G. Scopolamine administration modulates muscarinic, nicotinic and NMDA receptor systems. PLoS One. 2012;7(2):e32082 10.1371/journal.pone.0032082 ; PMCID: PMC3285663.
- Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. JAMA. 1998;280(20):1777–82. .
- Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med. 2012;2(5):a006148 10.1101/cshperspect.a006148 ; PMCID: PMC3331682.
- Puzzo D, Lee L, Palmeri A, Calabrese G, Arancio O. Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines. Biochem Pharmacol. 2014;88(4):450–67. 10.1016/j.bcp.2014.01.011 ; PMCID: PMC4014001.
- Goodrich-Hunsaker NJ, Hopkins RO. Spatial memory deficits in a virtual radial arm maze in amnesic participants with hippocampal damage. Behav Neurosci. 2010;124(3):405–13. 10.1037/a0019193 .
- Wilson WJ, Cook JA. Cholinergic manipulations and passive avoidance in the rat: effects on acquisition and recall. Acta Neurobiol Exp (Wars). 1994;54(4):377–91. .
- Garibotto V, Tettamanti M, Marcone A, Florea I, Panzacchi A, Moresco R, et al. Cholinergic activity correlates with reserve proxies in Alzheimer's disease. Neurobiol Aging. 2013;34(11):2694 e13–8. 10.1016/j.neurobiolaging.2013.05.020 .
- Craig LA, Hong NS, McDonald RJ. Revisiting the cholinergic hypothesis in the development of Alzheimer's disease. Neurosci Biobehav Rev. 2011;35(6):1397–409. 10.1016/j.neubiorev.2011.03.001 .
- Cutuli D, Foti F, Mandolesi L, De Bartolo P, Gelfo F, Federico F, et al. Cognitive performances of cholinergically depleted rats following chronic donepezil administration. J Alzheimers Dis. 2009;17(1):161–76. 10.3233/JAD-2009-1040 .
- Tota S, Hanif K, Kamat PK, Najmi AK, Nath C. Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function. Psychopharmacology (Berl). 2012;222(2):185–202. 10.1007/s00213-012-2639-7 .
- Doralp S, Leung LS. Cholinergic modulation of hippocampal CA1 basal-dendritic long-term potentiation. Neurobiol Learn Mem. 2008;90(2):382–8. 10.1016/j.nlm.2008.05.013 .
- Kida S. A Functional Role for CREB as a Positive Regulator of Memory Formation and LTP. Exp Neurobiol. 2012;21(4):136–40. 10.5607/en.2012.21.4.136 ; PMCID: PMC3538177.
- Walton MR, Dragunow I. Is CREB a key to neuronal survival? Trends Neurosci. 2000;23(2):48–53. S0166-2236(99)01500-3 .
- Deogracias R, Espliguero G, Iglesias T, Rodriguez-Pena A. Expression of the neurotrophin receptor trkB is regulated by the cAMP/CREB pathway in neurons. Mol Cell Neurosci. 2004;26(3):470–80. 10.1016/j.mcn.2004.03.007 .
- O'Bryant SE, Hobson V, Hall JR, Waring SC, Chan W, Massman P, et al. Brain-derived neurotrophic factor levels in Alzheimer's disease. J Alzheimers Dis. 2009;17(2):337–41. 10.3233/JAD-2009-1051
- Schmitt U, Tanimoto N, Seeliger M, Schaeffel F, Leube RE. Detection of behavioral alterations and learning deficits in mice lacking synaptophysin. Neuroscience. 2009;162(2):234–43. 10.1016/j.neuroscience.2009.04.046 .
- Birch AM, Kelly AM. Chronic intracerebroventricular infusion of nerve growth factor improves recognition memory in the rat. Neuropharmacology. 2013;75:255–61. 10.1016/j.neuropharm.2013.07.023 .
- Brinton RD, Wang JM. Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer's disease: allopregnanolone as a proof of concept neurogenic agent. Curr Alzheimer Res. 2006;3(3):185–90. PubMed .
- Hagg T. From neurotransmitters to neurotrophic factors to neurogenesis. Neuroscientist. 2009;15(1):20–7. 10.1177/1073858408324789
- Erickson KI, Prakash RS, Voss MW, Chaddock L, Heo S, McLaren M, et al. Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume. J Neurosci. 2010;30(15):5368–75. 10.1523/j.neuroscience.2010.6251-09
- Imam A, Ajao MS, Ajibola MI, Amin A, Abdulmajeed WI, Lawal AZ, et al. Black seed oil ameliorated scopolamine-induced memory dysfunction and cortico-hippocampal neural alterations in male Wistar rats. Bulletin of Faculty of Pharmacy, Cairo University. 2016;54(1):49–57. 10.1016/j.bfopcu.2015.12.005
Source: PubMed